We have three projects in the South Asian region of Bangladesh. Bangladesh with 160 million people is the 7th largest country by population and is a high growth market. It is one of the Next-11 (N-11) listed countries published by Goldman Sachs. While the country has always been an agriculture major country the economy has been accelerated in recent decades by the apparels (garments) and pharmaceuticals industries. In recent years, on national (government funded) and private levels there has been a growing interest and investment in biotechnology capacity to develop the agriculture, health and biopharma sectors and also to bring these up to global standards. To this end, sponsored by the Bangladeshi government, the genome of jute, the most important cash crop, was sequenced recently by local scientists, and sponsored by a private agribusiness, the genome of the buffalo was sequenced in collaboration with the BGI.
ImmunoSYS has focused on the biopharma and agribusiness sectors of Bangladesh. We work with three large companies on individual projects:
- A project with Healthcare Pharmaceuticals Ltd (HPL), a fast growing pharma company that grew out of the Roche team, is working to develop laboratory and animal facilities, core biological teams and processes to enable them the R&D and manufacture of antibodies, immune assays and kits, probiotics, bio-equivalence (BE) analysis, ADME and DMPK, peptides and proteins.
- A project with Phenix Group, one of the largest livestock companies, is working to develop laboratory and animal facilities, processes and to form consortium with academic groups in Bangladesh and the UK to enable them R&D and manufacture of veterinary vaccines, probiotics (for humans and livestock), enzymes and chromium-resistant bacteria.
- A project with Lal Teer, one of the largest and pioneering agricultural companies, is working to develop laboratory facilities to study and improve (gene modification) seeds, plants and bovine species. Lal Teer is a privately owned business which in 2014 sequenced the buffalo genome in collaboration with the Bejing Genome Institute (BGI), with a view to improving the cattle and dairy industries in Bangladesh.
- A project is in development to set up a research lab-clinic to install a cutting-edge screening technology (cell culture and biomarker based) from a UK university hospital to help patients who suffer from IVF failures and/or Recurrent Pregnancy Loss (RPL). This project, when finalised and implemented, will run in collaboration (technical support) with the UK-based hospital and will support the on-going research in the UK.